Siklos

DRUG2 trials

Sponsors

Theravia

Conditions

Renal Function DisorderSickle Cell Disease

Phase 4

Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)

CompletedNCT02522104

TheraviaRenal Function Disorder, Sickle Cell Disease

Start: 2015-09-03End: 2016-11-28Updated: 2021-10-12

Unknown Phase

European Sickle Cell Disease Cohort - Hydroxyurea

CompletedNCT02516579

TheraviaSickle Cell Disease

Start: 2009-01-31End: 2019-03-20Updated: 2020-03-19

Related Papers

Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase <scp>I</scp>/<scp>II REACH</scp> trial

American Journal of Hematology2024-02-086 citations

Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort—Hydroxyurea (<scp>ESCORT‐HU</scp>) study

American Journal of Hematology2024-01-229 citations